

# CLEC12A/MICL/CLL-1

Catalog # PVGS1837

## Product Information

---

<b>Primary Accession Species</b>	<a href="#">Q5QGZ9-2</a> Human
<b>Sequence</b>	His65-Ala265
<b>Purity</b>	> 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
<b>Endotoxin Level</b>	Less than 1EU per $\mu$ g by the LAL method.
<b>Biological Activity</b>	Immobilized Anti-CLEC12A Antibody, hFc Tag at 1 $\mu$ g/ml (100 $\mu$ l/Well) on the plate can bind CLEC12A/MICL/CLL-1 hFc Chimera[Biotin], Avi, Human (Cat.No.: Z03960)
<b>Expression System</b>	HEK293
<b>Theoretical Molecular Weight</b>	51.7 kDa
<b>Formulation</b>	Lyophilized from a 0.22 $\mu$ m filtered solution in PBS, (pH 7.4).
<b>Reconstitution</b>	It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH <sub>2</sub> O more than 100 $\mu$ g/ml.
<b>Storage &amp; Stability</b>	Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

## Additional Information

---

<b>Target Background</b>	CLEC12A, also known as CLL-1 is inhibitory C-type lectin-like receptor with ITIM motif. It can associate with signaling phosphatases SHP-1 and SHP-2. CLEC12A is a potential target due to its high expression in acute myeloid leukemia (AML) cells. And there are various therapeutic approaches using CLEC12A as a target for AML, such as CD3/ CLEC12A antibody. It can recruit unstimulated primary T cells against cancer cells with CLL-1 on the surface.
--------------------------	--

## Protein Information

---

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.